Samil Pharmaceutical Co.,Ltd Stock

Equities

A000520

KR7000520007

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
9,350 KRW +1.08% Intraday chart for Samil Pharmaceutical Co.,Ltd -4.00% +39.55%
Sales 2022 180B 131M Sales 2023 196B 143M Capitalization 96.9B 70.54M
Net income 2022 -28M -20.38K Net income 2023 1.66B 1.21M EV / Sales 2022 1.48 x
Net Debt 2022 157B 115M Net Debt 2023 175B 127M EV / Sales 2023 1.38 x
P/E ratio 2022
-3,837 x
P/E ratio 2023
58.3 x
Employees 548
Yield 2022 *
-
Yield 2023
-
Free-Float 59.55%
More Fundamentals * Assessed data
Dynamic Chart
Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Samil Pharmaceutical Co.,Ltd announced that it has received KRW 12 billion in funding CI
Samil Pharmaceutical Co.,Ltd announced that it expects to receive KRW 12 billion in funding CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 30, 2021. CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 30, 2021. CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 30, 2021. CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 30, 2021. CI
Samil Pharmaceutical Co.,Ltd's Equity Buyback announced on November 30, 2021, has expired with 125,939 shares, representing 0.99% for KRW 997.71 million. CI
Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on October 5, 2021. CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on October 5, 2021. CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on October 5, 2021. CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on October 5, 2021. CI
More news
1 day+1.08%
1 week-4.00%
Current month-19.33%
1 month-10.95%
3 months-12.70%
6 months+52.53%
Current year+39.55%
More quotes
1 week
9 080.00
Extreme 9080
9 770.00
1 month
9 080.00
Extreme 9080
12 650.00
Current year
6 560.00
Extreme 6560
12 650.00
1 year
5 690.00
Extreme 5690
12 650.00
3 years
5 690.00
Extreme 5690
12 650.00
5 years
4 545.45
Extreme 4545.4545
15 977.27
10 years
2 404.55
Extreme 2404.5455
29 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 -
Chief Executive Officer 42 -
Chief Tech/Sci/R&D Officer 52 -
Members of the board TitleAgeSince
Chief Executive Officer 42 -
Director/Board Member 59 -
Director/Board Member 39 -
More insiders
Date Price Change Volume
24-04-24 9,350 +1.08% 302,610
24-04-23 9,250 -0.32% 186,612
24-04-22 9,280 +0.87% 307,378
24-04-19 9,200 -5.74% 536,414
24-04-18 9,760 +0.21% 267,502

End-of-day quote Korea S.E., April 23, 2024

More quotes
SAMIL PHARMACEUTICAL CO., LTD is a Korea-based company mainly engaged in the manufacture of medicines. The Company’s products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The Company distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.
More about the company
  1. Stock Market
  2. Equities
  3. A000520 Stock